Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 8Classical hematology 8Other hematologic neoplasm 7Lymphoid 7Other neoplasm 5Dermatologic 3Thoracic 1Myeloid 1Breast 1

Conditions

Lung Neoplasms 3Anemia 3Multiple Myeloma 2Lymphoma 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms 2Small Cell Lung Carcinoma 1Prostatic Neoplasms 1Precancerous Conditions 1Ovarian Neoplasms 1Neoplasms, Plasma Cell 1Neoplasms 1Myeloproliferative Disorders 1Leukemia 1Esophageal Neoplasms 1Drug-Related Side Effects and Adverse Reactions 1Adenocarcinoma, Bronchiolo-Alveolar 1Adenocarcinoma of Lung 1

Interventions

saracatinib 1resiquimod 1poly ICLC 1pembrolizumab 1orantinib 1motexafin gadolinium 1cediranib 1Epoetin Alfa 1Doxorubicin 1Azacitidine 14-phenylbutyric acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms, Plasma Cell × Epoetin Alfa × Thoracic × Clear all
NCT00003600 2016-07-13

Epoetin Alfa in Treating Anemia in Patients Who Are Receiving Chemotherapy

Alliance for Clinical Trials in Oncology

Phase 3 Completed
344 enrolled
BreastClassical hematologyLymphoidMyeloidOther hematologic neoplasmOther neoplasmPlasma cellThoracic

Anemia, Breast Neoplasms, Leukemia, Lung Neoplasms, Lymphoma, Multiple Myeloma, Myeloproliferative Disorders, Precancerous Conditions, Neoplasms, Plasma Cell, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡